Serdexmethylphenidate (SDX) is a prodrug of dexmethylphenidate created by the pharmaceutical company Zevra Therapeutics. The compound was first approved by the FDA as one of the active ingredients in Azstarys for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults in March 2021.
Serdexmethylphenidate (SDX) is a prodrug of dexmethylphenidate created by the pharmaceutical company Zevra Therapeutics. The compound was first approved by the FDA as one of the active ingredients in Azstarys for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults in March 2021.
Source: Wikipedia "Serdexmethylphenidate" · CC BY-SA 4.0
Share this article: X · Bluesky